The RNA delivery LNP kit for the NanoAssemblr™ Ignite™ and Ignite+™ systems offers ready–to–use ionizable lipid mix and buffers to fast-track payload screening and RNA drug delivery validation, progressing lead candidates quickly through preclinical studies accelerating clinical evaluation.
- Preoptimized ionizable lipid mix for RNA-LNP delivery to accelerate lead candidate selection
- Rapid and easy prep of high-quality, stable LNPs using prepared reagents and protocols
- Easily scalable on the NanoAssemblr™ system platform
- Includes in vitro protein expression and in vivo immunogenicity proof-of-concept data for mRNA vaccine applications, validated for reproducible, high-quality LNP production and stability, up to clinical and commercial nanomedicine manufacturing.
*LNP composition in this research-use-only kit includes an ionizable lipid excipient that can be licensed for future clinical evaluation.
Streamline payload screening and lead candidate optimization
Off-the-shelf reagent kits offer easy screening of RNA payloads and lead candidate optimization for physicochemical attributes and potency to fast-track lead candidate selection for RNA drug delivery.
Graphs above show (left) the LNP size and polydispersity (PDI), and (right) the encapsulation efficiency of LNPs, prepared using the RNA delivery LNP kit with both mRNA and self-amplifying RNA encoding for different antigens.
LNPs were prepared using the RNA delivery LNP kit and mRNA encoding for haemagglutinin (HA), a surface protein on the H1N1 virus. LNPs were used to immunize BALB/c mice with a primary and booster dose of 2 μg RNA on days 0 and 28 of the immunization schedule. The immunogenicity of LNPs is shown in the graph above, showing the HA inhibition titers using serum sampled on days 21 and 42.
Quality RNA-LNP formulations
The RNA delivery LNP kit consistently produces quality LNPs that are highly effective in protecting encapsulated nucleic acids, maintaining critical quality attributes (CQAs) and potency over time.
Storage stability and CQA consistency of LNPs produced with the RNA delivery LNP kit, prepared with cryopreservation buffer, over 1 week of storage under refrigerated conditions and 6 weeks of storage at -80°C.
In vitro potency of lead candidate LNPs encapsulating (A) eGFP mRNA or (B) eGFP saRNA in HEK-293 cells over 1 week of storage under refrigerated conditions and 6 weeks of storage at -80°C.
Scalable NxGen™ technology
Genomic medicine success starts at the discovery phase, by validating RNA drug delivery with ionizable lipid compositions and LNP technologies at a small scale. This allows for consistent LNP formulation using the NanoAssemblr™ NxGen™ platform for clinical evaluation and commercial production.
Immunogenicity of saRNA-LNPs prepared using NanoAssemblr™ NxGen™ technology at different scales, showing the log-transformed SARS-CoV-2 spike protein specific IgG titers in serum of BALB/c mice treated with lead candidate saRNA-LNPs.
Kit components
| |
RNA delivery LNP kit, 3 mL
1002569 |
RNA delivery LNP kit, 6 mL
1002471 |
| Lipid mix |
3 mL |
6 mL |
| Formulation buffer |
6 mL |
6 mL |
| Dilution buffer |
100 mL |
100 mL |
| Cryopreservation buffer |
12 mL |
12 mL |
Documents
